Location History:
- Kasterlee, BE (2006)
- Buckingham, GB (2007)
Company Filing History:
Years Active: 2006-2007
Title: Alan Richardson: Innovator in Pharmaceutical Science
Introduction
Alan Richardson is a notable inventor based in Buckingham, GB. He has made significant contributions to the field of pharmaceutical science, particularly in the development of kinase inhibitors. With a total of 2 patents, his work has the potential to impact the treatment of various cell proliferative disorders.
Latest Patents
Richardson's latest patents include innovative compounds such as 3-furanyl analogs of toxoflavine, which serve as inhibitors of cyclin-dependent serine/threonine kinases (Cdks). These compounds are designed to target kinases and phosphatases involved in cell cycle regulation, including tyrosine kinases like Wee1, Mik1, and Myt1. Additionally, his patent on human Akt-3 encompasses a nucleic acid molecule encoding the human Akt-3 protein, which can be utilized in the treatment of cancer.
Career Highlights
Alan Richardson is currently associated with Janssen Pharmaceutica NV, where he continues to advance his research in pharmaceutical innovations. His work is characterized by a commitment to developing effective treatments for serious health conditions.
Collaborations
Richardson has collaborated with esteemed colleagues such as Jean Fernand Armand Lacrampe and Richard William Connors, contributing to a dynamic research environment that fosters innovation.
Conclusion
Alan Richardson's contributions to pharmaceutical science through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in the treatment of critical health issues.